FAQs
What are the deliverables of a standard lead development project?
A lead development project at QVQ is always custom made to meet the needs for your project. Often included are the delivery of single domain antibody phagemid libraries, masterplates of monoclonal antibodies, including individual sequences, and delivery of 0.2mg purified material of 10-12 lead candidates accompanied with experimental data.
Do you sacrifice the animals after immunization?
No, immunizations are done by accredited partners, and we only use a small volume of blood for serum titration and RNA extraction of PBMC’s. Animals are routinely reused for new campaigns after a resting period and are not sacrificed for the purpose of antibody development projects.
How does the no cure no pay work at QVQ?
A project is divided into different workpackages led by a dedicated project manager and together with the customer is decided whether the workpackage has been delivered. If not, QVQ will not invoice this workpackage. Thus, if no specific singe domain antibodies are found to the target of interest the panning and selection workpackage will not be invoiced.
What is the success rate of lead panel antibody delivery?
Since QVQ works with a no cure no pay policy, we make the effort to get high quality antibodies out of each project. This means that if we receive good quality immunogen and we use two animals to avoid the occasional bad responder, the success rate is >95%.
Who owns the IP of the project?
All intellectual property corresponding to the lead development project or the production, purification and characterization of single domain antibodies is transferred to the customer and is fully owned by the customer to allow protection and further development of the molecules.
Literature
View a list of publications that showcase our single-domain-antibody expertise here.
Application Notes
Directional conjugation of single-domain antibodies enables their application in fluorescence technologies and advanced imaging View